{"transactions":[{"id":1556370,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92443,"kind":"person","name":"Fairmount Healthcare Fund GP LLC","position":2,"cik":"0001830383","reported_name":"Fairmount Healthcare Fund GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":47598,"kind":"person","name":"Fairmount Healthcare Fund II GP LLC","position":3,"cik":"0001830382","reported_name":"Fairmount Healthcare Fund II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":4,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":5,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Non-Voting Convertible Preferred Stock","published_at":"2024-04-01T18:32:37.000Z","date":"2024-03-28","kind":"other","planned":false,"acquired":true,"shares":21999,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP (\"Fund I\"), all shares of common stock and Series A Non-Voting Convertible Preferred Stock held by Fund I were transferred to Fairmount Healthcare Fund II LP (\"Fund II\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the securities held by Fund II. They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein."}],"balance_after":133191,"derivative":{"underlying":"Common Stock","underlying_shares":1466673},"source":{"system":"sec-edgar","filing":"0000950170-24-039599","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000095017024039599/ownership.xml","form_type":"4"}},{"id":1556369,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92443,"kind":"person","name":"Fairmount Healthcare Fund GP LLC","position":2,"cik":"0001830383","reported_name":"Fairmount Healthcare Fund GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":47598,"kind":"person","name":"Fairmount Healthcare Fund II GP LLC","position":3,"cik":"0001830382","reported_name":"Fairmount Healthcare Fund II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":4,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":5,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Non-Voting Convertible Preferred Stock","published_at":"2024-04-01T18:32:37.000Z","date":"2024-03-28","kind":"other","planned":false,"acquired":false,"shares":21999,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP (\"Fund I\"), all shares of common stock and Series A Non-Voting Convertible Preferred Stock held by Fund I were transferred to Fairmount Healthcare Fund II LP (\"Fund II\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the securities held by Fund I. They disclaim beneficial ownership of securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1466673},"source":{"system":"sec-edgar","filing":"0000950170-24-039599","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000095017024039599/ownership.xml","form_type":"4"}},{"id":1556368,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92443,"kind":"person","name":"Fairmount Healthcare Fund GP LLC","position":2,"cik":"0001830383","reported_name":"Fairmount Healthcare Fund GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":47598,"kind":"person","name":"Fairmount Healthcare Fund II GP LLC","position":3,"cik":"0001830382","reported_name":"Fairmount Healthcare Fund II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":4,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":5,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-01T18:32:37.000Z","date":"2024-03-28","kind":"other","planned":false,"acquired":true,"shares":5859,"ownership":{"direct":false,"nature":"Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP (\"Fund I\"), all shares of common stock and Series A Non-Voting Convertible Preferred Stock held by Fund I were transferred to Fairmount Healthcare Fund II LP (\"Fund II\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP (\"Fund I\"), all shares of common stock and Series A Non-Voting Convertible Preferred Stock held by Fund I were transferred to Fairmount Healthcare Fund II LP (\"Fund II\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the securities held by Fund II. They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein."}],"balance_after":1845813,"source":{"system":"sec-edgar","filing":"0000950170-24-039599","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000095017024039599/ownership.xml","form_type":"4"}},{"id":1556367,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92443,"kind":"person","name":"Fairmount Healthcare Fund GP LLC","position":2,"cik":"0001830383","reported_name":"Fairmount Healthcare Fund GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":47598,"kind":"person","name":"Fairmount Healthcare Fund II GP LLC","position":3,"cik":"0001830382","reported_name":"Fairmount Healthcare Fund II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":4,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":5,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-01T18:32:37.000Z","date":"2024-03-28","kind":"other","planned":false,"acquired":false,"shares":5859,"ownership":{"direct":false,"nature":"Fairmount Healthcare Fund LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP (\"Fund I\"), all shares of common stock and Series A Non-Voting Convertible Preferred Stock held by Fund I were transferred to Fairmount Healthcare Fund II LP (\"Fund II\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP (\"Fund I\"), all shares of common stock and Series A Non-Voting Convertible Preferred Stock held by Fund I were transferred to Fairmount Healthcare Fund II LP (\"Fund II\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the securities held by Fund I. They disclaim beneficial ownership of securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-039599","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000095017024039599/ownership.xml","form_type":"4"}},{"id":1556374,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":2,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":4,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":5,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Voting Common Stock","published_at":"2024-04-01T17:44:38.000Z","date":"2024-03-28","kind":"other","planned":false,"acquired":true,"shares":221426,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The shares of non-voting common stock have no expiration date and are convertible in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time at the option of the holder into shares of common stock of the Issuer on a 1-for-1 basis without consideration to the extent that after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of common stock immediately prior to and following such conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer, provided that the percentage may not exceed 19.99%."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP (\"Fund I\"), all shares of common stock and non-voting common stock held by Fund I were transferred to Fairmount Healthcare Fund II LP (\"Fund II\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of non-voting common stock have no expiration date and are convertible in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time at the option of the holder into shares of common stock of the Issuer on a 1-for-1 basis without consideration to the extent that after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of common stock immediately prior to and following such conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer, provided that the percentage may not exceed 19.99%."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of non-voting common stock have no expiration date and are convertible in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time at the option of the holder into shares of common stock of the Issuer on a 1-for-1 basis without consideration to the extent that after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of common stock immediately prior to and following such conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer, provided that the percentage may not exceed 19.99%."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of common stock and non-voting common stock held by Fund II. Peter Harwin and Tomas Kiselak are the Managing Members of Fairmount Healthcare Fund II GP LLC. Fairmount Funds Management LLC, Fairmount Healthcare Fund II GP LLC, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein."}],"balance_after":6743321,"derivative":{"underlying":"Common Stock","underlying_shares":6521895},"source":{"system":"sec-edgar","filing":"0001104659-24-041998","document":"tm2410305-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000110465924041998/tm2410305-2_4seq1.xml","form_type":"4"}},{"id":1556373,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":2,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":4,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":5,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Voting Common Stock","published_at":"2024-04-01T17:44:38.000Z","date":"2024-03-28","kind":"other","planned":false,"acquired":false,"shares":221426,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The shares of non-voting common stock have no expiration date and are convertible in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time at the option of the holder into shares of common stock of the Issuer on a 1-for-1 basis without consideration to the extent that after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of common stock immediately prior to and following such conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer, provided that the percentage may not exceed 19.99%."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP (\"Fund I\"), all shares of common stock and non-voting common stock held by Fund I were transferred to Fairmount Healthcare Fund II LP (\"Fund II\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of non-voting common stock have no expiration date and are convertible in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time at the option of the holder into shares of common stock of the Issuer on a 1-for-1 basis without consideration to the extent that after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of common stock immediately prior to and following such conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer, provided that the percentage may not exceed 19.99%."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of non-voting common stock have no expiration date and are convertible in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time at the option of the holder into shares of common stock of the Issuer on a 1-for-1 basis without consideration to the extent that after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of common stock immediately prior to and following such conversion, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer, provided that the percentage may not exceed 19.99%."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the shares of common stock and non-voting common stock held by Fund I. Peter Harwin and Tomas Kiselak are the Managing Members of Fairmount Healthcare Fund GP LLC. Fairmount Funds Management LLC, Fairmount Healthcare Fund GP LLC, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":221426},"source":{"system":"sec-edgar","filing":"0001104659-24-041998","document":"tm2410305-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000110465924041998/tm2410305-2_4seq1.xml","form_type":"4"}},{"id":1556372,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":2,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":4,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":5,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-01T17:44:38.000Z","date":"2024-03-28","kind":"other","planned":false,"acquired":true,"shares":55913,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP (\"Fund I\"), all shares of common stock and non-voting common stock held by Fund I were transferred to Fairmount Healthcare Fund II LP (\"Fund II\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP (\"Fund I\"), all shares of common stock and non-voting common stock held by Fund I were transferred to Fairmount Healthcare Fund II LP (\"Fund II\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of common stock and non-voting common stock held by Fund II. Peter Harwin and Tomas Kiselak are the Managing Members of Fairmount Healthcare Fund II GP LLC. Fairmount Funds Management LLC, Fairmount Healthcare Fund II GP LLC, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein."}],"balance_after":2048647,"source":{"system":"sec-edgar","filing":"0001104659-24-041998","document":"tm2410305-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000110465924041998/tm2410305-2_4seq1.xml","form_type":"4"}},{"id":1556371,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":2,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":4,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":5,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-01T17:44:38.000Z","date":"2024-03-28","kind":"other","planned":false,"acquired":false,"shares":55913,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP (\"Fund I\"), all shares of common stock and non-voting common stock held by Fund I were transferred to Fairmount Healthcare Fund II LP (\"Fund II\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 28, 2024, in connection with the wind down of Fairmount Healthcare Fund LP (\"Fund I\"), all shares of common stock and non-voting common stock held by Fund I were transferred to Fairmount Healthcare Fund II LP (\"Fund II\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the shares of common stock and non-voting common stock held by Fund I. Peter Harwin and Tomas Kiselak are the Managing Members of Fairmount Healthcare Fund GP LLC. Fairmount Funds Management LLC, Fairmount Healthcare Fund GP LLC, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-24-041998","document":"tm2410305-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000110465924041998/tm2410305-2_4seq1.xml","form_type":"4"}},{"id":1665211,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":2,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":94756,"kind":"person","name":"Fairmount Healthcare Co-Invest II L.P.","position":4,"cik":"0001982189","reported_name":"Fairmount Healthcare Co-Invest II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":5,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":6,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-31T16:31:31.000Z","date":"2024-01-29","kind":"other","planned":true,"acquired":true,"shares":51166,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Peter Harwin"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Fairmount Healthcare Co-Invest II LP (\"Co-Invest\") to its limited partners pursuant to a Rule 10b5-1 trading plan adopted by Co-Invest on September 29, 2023."}],"balance_after":51166,"source":{"system":"sec-edgar","filing":"0001104659-24-008835","document":"tm244753-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000110465924008835/tm244753-2_4seq1.xml","form_type":"4"}},{"id":1665210,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":2,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":94756,"kind":"person","name":"Fairmount Healthcare Co-Invest II L.P.","position":4,"cik":"0001982189","reported_name":"Fairmount Healthcare Co-Invest II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":5,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":6,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-31T16:31:31.000Z","date":"2024-01-29","kind":"other","planned":true,"acquired":true,"shares":51166,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Tomas Kiselak"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Fairmount Healthcare Co-Invest II LP (\"Co-Invest\") to its limited partners pursuant to a Rule 10b5-1 trading plan adopted by Co-Invest on September 29, 2023."}],"balance_after":51166,"source":{"system":"sec-edgar","filing":"0001104659-24-008835","document":"tm244753-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000110465924008835/tm244753-2_4seq1.xml","form_type":"4"}},{"id":1665209,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":2,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":94756,"kind":"person","name":"Fairmount Healthcare Co-Invest II L.P.","position":4,"cik":"0001982189","reported_name":"Fairmount Healthcare Co-Invest II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":5,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":6,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-31T16:31:31.000Z","date":"2024-01-29","kind":"other","planned":true,"acquired":false,"shares":892529,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Co-Invest II LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Fairmount Healthcare Co-Invest II LP (\"Co-Invest\") to its limited partners pursuant to a Rule 10b5-1 trading plan adopted by Co-Invest on September 29, 2023."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund L.P. (\"Fund I\"), Fairmount Healthcare Fund II L.P. (\"Fund II\") and Co-Invest. The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-24-008835","document":"tm244753-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000110465924008835/tm244753-2_4seq1.xml","form_type":"4"}},{"id":1672036,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":92443,"kind":"person","name":"Fairmount Healthcare Fund GP LLC","position":2,"cik":"0001830383","reported_name":"Fairmount Healthcare Fund GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":47598,"kind":"person","name":"Fairmount Healthcare Fund II GP LLC","position":3,"cik":"0001830382","reported_name":"Fairmount Healthcare Fund II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":4,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":5,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}}],"security":"Common Stock","published_at":"2024-01-24T18:44:41.000Z","date":"2024-01-22","kind":"purchase","planned":false,"acquired":true,"shares":476190,"price":21,"value":9999990.0,"ownership":{"direct":false,"nature":"Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the securities held by Fairmount Healthcare Fund II LP (\"Fund II\"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein."}],"balance_after":1839954,"source":{"system":"sec-edgar","filing":"0000950170-24-007123","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000095017024007123/ownership.xml","form_type":"4"}},{"id":1697956,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":2,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95736,"kind":"person","name":"Fairmount Healthcare Co-Invest L.P.","position":4,"cik":"0001982220","reported_name":"Fairmount Healthcare Co-Invest L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":5,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":6,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-12-29T17:00:07.000Z","date":"2023-12-29","kind":"other","planned":true,"acquired":true,"shares":406038,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Peter Harwin"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Fairmount Healthcare Co-Invest L.P. (\"Co-Invest\") to its limited partners pursuant to a Rule 10b5-1 trading plan adopted by Co-Invest on September 29, 2023."}],"balance_after":406038,"source":{"system":"sec-edgar","filing":"0000950170-23-073904","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000095017023073904/ownership.xml","form_type":"4"}},{"id":1697955,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":2,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95736,"kind":"person","name":"Fairmount Healthcare Co-Invest L.P.","position":4,"cik":"0001982220","reported_name":"Fairmount Healthcare Co-Invest L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":5,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":6,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-12-29T17:00:07.000Z","date":"2023-12-29","kind":"other","planned":true,"acquired":true,"shares":406038,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Tomas Kiselak"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Fairmount Healthcare Co-Invest L.P. (\"Co-Invest\") to its limited partners pursuant to a Rule 10b5-1 trading plan adopted by Co-Invest on September 29, 2023."}],"balance_after":406038,"source":{"system":"sec-edgar","filing":"0000950170-23-073904","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000095017023073904/ownership.xml","form_type":"4"}},{"id":1697954,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":2,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95736,"kind":"person","name":"Fairmount Healthcare Co-Invest L.P.","position":4,"cik":"0001982220","reported_name":"Fairmount Healthcare Co-Invest L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":5,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":6,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-12-29T17:00:07.000Z","date":"2023-12-29","kind":"other","planned":true,"acquired":false,"shares":3435480,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Co-Invest L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Fairmount Healthcare Co-Invest L.P. (\"Co-Invest\") to its limited partners pursuant to a Rule 10b5-1 trading plan adopted by Co-Invest on September 29, 2023."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund L.P. (\"Fund I\"), Fairmount Healthcare Fund II L.P. (\"Fund II\") and Co-Invest. The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-23-073904","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000095017023073904/ownership.xml","form_type":"4"}},{"id":1716308,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":2,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95736,"kind":"person","name":"Fairmount Healthcare Co-Invest L.P.","position":4,"cik":"0001982220","reported_name":"Fairmount Healthcare Co-Invest L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":5,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":6,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2023-12-11T17:41:01.000Z","date":"2023-12-07","kind":"grant","planned":false,"acquired":true,"shares":16667,"price":600,"value":10000200.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Following stockholder approval of the conversion of the Series B non-voting convertible preferred stock (the \"Series B Preferred Stock\") into shares of Common Stock, each share of Series B Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 0.00% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares of Series B Preferred Stock were purchased from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Following stockholder approval of the conversion of the Series B non-voting convertible preferred stock (the \"Series B Preferred Stock\") into shares of Common Stock, each share of Series B Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 0.00% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Following stockholder approval of the conversion of the Series B non-voting convertible preferred stock (the \"Series B Preferred Stock\") into shares of Common Stock, each share of Series B Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 0.00% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":16667,"derivative":{"underlying":"Common Stock","underlying_shares":666680},"source":{"system":"sec-edgar","filing":"0000950170-23-069455","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000095017023069455/ownership.xml","form_type":"4"}},{"id":1728666,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":2,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95736,"kind":"person","name":"Fairmount Healthcare Co-Invest L.P.","position":4,"cik":"0001982220","reported_name":"Fairmount Healthcare Co-Invest L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":5,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":6,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2023-11-28T16:05:26.000Z","date":"2023-11-24","kind":"exercise","planned":false,"acquired":false,"shares":85887,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Co-Invest L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain beneficial ownership limitations."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain beneficial ownership limitations."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain beneficial ownership limitations."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund L.P., Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest L.P. The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3435480},"source":{"system":"sec-edgar","filing":"0000950170-23-066399","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000095017023066399/ownership.xml","form_type":"4"}},{"id":1728665,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":2,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":95736,"kind":"person","name":"Fairmount Healthcare Co-Invest L.P.","position":4,"cik":"0001982220","reported_name":"Fairmount Healthcare Co-Invest L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":5,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":6,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-11-28T16:05:26.000Z","date":"2023-11-24","kind":"exercise","planned":false,"acquired":true,"shares":3435480,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Co-Invest L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain beneficial ownership limitations."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund L.P., Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest L.P. The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":3435480,"source":{"system":"sec-edgar","filing":"0000950170-23-066399","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000095017023066399/ownership.xml","form_type":"4"}},{"id":1752469,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":92443,"kind":"person","name":"Fairmount Healthcare Fund GP LLC","position":2,"cik":"0001830383","reported_name":"Fairmount Healthcare Fund GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":47598,"kind":"person","name":"Fairmount Healthcare Fund II GP LLC","position":3,"cik":"0001830382","reported_name":"Fairmount Healthcare Fund II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":4,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":5,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}}],"security":"Series B Non-Voting Convertible Preferred Stock","published_at":"2023-11-01T21:05:00.000Z","date":"2023-10-30","kind":"grant","planned":false,"acquired":true,"shares":48463,"price":825.3746,"value":40000129.2398,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B non-voting convertible preferred stock is convertible into shares of the Issuer's common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series B non-voting convertible preferred stock is prohibited from converting shares of Series B non-voting convertible preferred stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares of Series B non-voting convertible preferred stock were purchased from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B non-voting convertible preferred stock is convertible into shares of the Issuer's common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series B non-voting convertible preferred stock is prohibited from converting shares of Series B non-voting convertible preferred stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B non-voting convertible preferred stock is convertible into shares of the Issuer's common stock at any time at the option of the holder thereof, into 66.67 shares of common stock, subject to certain limitations, including that a holder of Series B non-voting convertible preferred stock is prohibited from converting shares of Series B non-voting convertible preferred stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of common stock and Series B non-voting convertible preferred stock held by Fairmount Healthcare Fund II LP (\"Fund II\"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein."}],"balance_after":48463,"derivative":{"underlying":"Common Stock","underlying_shares":3231028.21},"source":{"system":"sec-edgar","filing":"0000950170-23-057692","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000095017023057692/ownership.xml","form_type":"4"}},{"id":1828691,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":2,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":94756,"kind":"person","name":"Fairmount Healthcare Co-Invest II L.P.","position":4,"cik":"0001982189","reported_name":"Fairmount Healthcare Co-Invest II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":5,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":6,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-17T20:00:23.000Z","date":"2023-07-13","kind":"grant","planned":false,"acquired":true,"shares":47758,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option represents the right to purchase 47,758 shares of the Issuer's common stock, and will vest in three approximately equal annual installments beginning on the first anniversary of the grant date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak holds the option for one or more Fairmount Funds. Mr. Kiselak is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":47758,"derivative":{"exercise_price":17,"expiration_date":"2033-07-13","underlying":"Common Stock","underlying_shares":47758},"source":{"system":"sec-edgar","filing":"0001104659-23-081729","document":"tm2321456-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000110465923081729/tm2321456-6_4seq1.xml","form_type":"4"}},{"id":1828690,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":2,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":94756,"kind":"person","name":"Fairmount Healthcare Co-Invest II L.P.","position":4,"cik":"0001982189","reported_name":"Fairmount Healthcare Co-Invest II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":5,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":6,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-17T20:00:23.000Z","date":"2023-07-13","kind":"grant","planned":false,"acquired":true,"shares":47758,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option represents the right to purchase 47,758 shares of the Issuer's common stock, and will vest in three approximately equal annual installments beginning on the first anniversary of the grant date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Under Mr. Harwin's arrangement with Fairmount, Mr. Harwin holds the option for one or more investment vehicles managed by Fairmount (each, a \"Fairmount Fund\"). Mr. Harwin is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":47758,"derivative":{"exercise_price":17,"expiration_date":"2033-07-13","underlying":"Common Stock","underlying_shares":47758},"source":{"system":"sec-edgar","filing":"0001104659-23-081729","document":"tm2321456-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000110465923081729/tm2321456-6_4seq1.xml","form_type":"4"}},{"id":1828689,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":2,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":94756,"kind":"person","name":"Fairmount Healthcare Co-Invest II L.P.","position":4,"cik":"0001982189","reported_name":"Fairmount Healthcare Co-Invest II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":5,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":6,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-17T20:00:23.000Z","date":"2023-07-13","kind":"purchase","planned":false,"acquired":true,"shares":892529,"price":17,"value":15172993.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Co-Invest II LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund LP, Fairmount Healthcare Fund II LP and Fairmount Healthcare Co-Invest II LP. The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":892529,"source":{"system":"sec-edgar","filing":"0001104659-23-081729","document":"tm2321456-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000110465923081729/tm2321456-6_4seq1.xml","form_type":"4"}},{"id":1828688,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":2,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":94756,"kind":"person","name":"Fairmount Healthcare Co-Invest II L.P.","position":4,"cik":"0001982189","reported_name":"Fairmount Healthcare Co-Invest II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":5,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":6,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-17T20:00:23.000Z","date":"2023-07-13","kind":"purchase","planned":false,"acquired":true,"shares":1992734,"price":17,"value":33876478.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund LP, Fairmount Healthcare Fund II LP and Fairmount Healthcare Co-Invest II LP. The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":1992734,"source":{"system":"sec-edgar","filing":"0001104659-23-081729","document":"tm2321456-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000110465923081729/tm2321456-6_4seq1.xml","form_type":"4"}},{"id":1828687,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":2,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":3,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":94756,"kind":"person","name":"Fairmount Healthcare Co-Invest II L.P.","position":4,"cik":"0001982189","reported_name":"Fairmount Healthcare Co-Invest II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":5,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":6,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-17T20:00:23.000Z","date":"2023-07-13","kind":"purchase","planned":false,"acquired":true,"shares":55913,"price":17,"value":950521.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund LP, Fairmount Healthcare Fund II LP and Fairmount Healthcare Co-Invest II LP. The general partner of Fairmount is Fairmount Funds Management GP LLC (\"Fairmount GP\"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":55913,"source":{"system":"sec-edgar","filing":"0001104659-23-081729","document":"tm2321456-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000110465923081729/tm2321456-6_4seq1.xml","form_type":"4"}},{"id":2178274,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See Remarks"}},{"id":92443,"kind":"person","name":"Fairmount Healthcare Fund GP LLC","position":2,"cik":"0001830383","reported_name":"Fairmount Healthcare Fund GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":47598,"kind":"person","name":"Fairmount Healthcare Fund II GP LLC","position":3,"cik":"0001830382","reported_name":"Fairmount Healthcare Fund II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":4,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":5,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-19T16:32:21.000Z","date":"2022-08-17","kind":"purchase","acquired":true,"shares":425531,"price":23.5,"value":9999978.5,"ownership":{"direct":false,"nature":"Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fairmount Healthcare Fund II LP (\"Fund II\"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein."}],"balance_after":1363764,"source":{"system":"sec-edgar","filing":"0001104659-22-092992","document":"tm2224209-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000110465922092992/tm2224209-1_4seq1.xml","form_type":"4"}},{"id":2560944,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92443,"kind":"person","name":"Fairmount Healthcare Fund GP LLC","position":2,"cik":"0001830383","reported_name":"Fairmount Healthcare Fund GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":47598,"kind":"person","name":"Fairmount Healthcare Fund II GP LLC","position":3,"cik":"0001830382","reported_name":"Fairmount Healthcare Fund II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":4,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":5,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}}],"security":"Common Stock","published_at":"2021-09-23T09:30:09.000Z","date":"2021-09-21","kind":"purchase","acquired":true,"shares":909000,"price":11,"value":9999000.0,"ownership":{"direct":false,"nature":"Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fairmount Healthcare Fund II LP (\"Fund II\"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein."}],"balance_after":938233,"source":{"system":"sec-edgar","filing":"0000899243-21-037255","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000089924321037255/doc4.xml","form_type":"4"}},{"id":2997476,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":92443,"kind":"person","name":"Fairmount Healthcare Fund GP LLC","position":2,"cik":"0001830383","reported_name":"Fairmount Healthcare Fund GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":47598,"kind":"person","name":"Fairmount Healthcare Fund II GP LLC","position":3,"cik":"0001830382","reported_name":"Fairmount Healthcare Fund II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":4,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":5,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}}],"security":"Series A Non-Voting Convertible Preferred Stock","published_at":"2020-10-30T11:53:55.000Z","date":"2020-10-30","kind":"purchase","acquired":true,"shares":28843,"price":465.96,"value":13439684.28,"ownership":{"direct":false,"nature":"Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fairmount Healthcare Fund II LP (\"Fund II\"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein."}],"balance_after":111192,"derivative":{"underlying":"Common Stock","underlying_shares":28483000},"source":{"system":"sec-edgar","filing":"0000899243-20-029904","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000089924320029904/doc4.xml","form_type":"4"}},{"id":2997475,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":92443,"kind":"person","name":"Fairmount Healthcare Fund GP LLC","position":2,"cik":"0001830383","reported_name":"Fairmount Healthcare Fund GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":47598,"kind":"person","name":"Fairmount Healthcare Fund II GP LLC","position":3,"cik":"0001830382","reported_name":"Fairmount Healthcare Fund II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":4,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":5,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}}],"security":"Series A Non-Voting Convertible Preferred Stock","published_at":"2020-10-30T11:53:55.000Z","date":"2020-10-30","kind":"purchase","acquired":true,"shares":5494,"price":465.96,"value":2559984.24,"ownership":{"direct":false,"nature":"Fairmount Healthcare Fund LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fairmount Healthcare Fund LP (\"Fund I\"). They disclaim beneficial ownership of securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein."}],"balance_after":21999,"derivative":{"underlying":"Common Stock","underlying_shares":5494000},"source":{"system":"sec-edgar","filing":"0000899243-20-029904","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000089924320029904/doc4.xml","form_type":"4"}},{"id":2998160,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":92443,"kind":"person","name":"Fairmount Healthcare Fund GP LLC","position":2,"cik":"0001830383","reported_name":"Fairmount Healthcare Fund GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":47598,"kind":"person","name":"Fairmount Healthcare Fund II GP LLC","position":3,"cik":"0001830382","reported_name":"Fairmount Healthcare Fund II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":4,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":5,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}}],"security":"Series A Non-Voting Convertible Preferred Stock","published_at":"2020-10-29T11:30:05.000Z","date":"2020-10-27","kind":"other","acquired":true,"shares":82349,"ownership":{"direct":false,"nature":"Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion"},{"field":"kind","element":"transactionCoding","label":"F2","text":"On October 27, 2020, Issuer completed its Merger with Viridian, in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020.  In connection with the Merger, Fairmount Healthcare Fund II LP (\"Fund II\") received such shares in exchange for 3,301,890 shares of Viridian Series Seed Preferred Stock and 4,159,388 shares of Viridian Series A Preferred Stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 27, 2020, Issuer completed its Merger with Viridian, in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020.  In connection with the Merger, Fairmount Healthcare Fund II LP (\"Fund II\") received such shares in exchange for 3,301,890 shares of Viridian Series Seed Preferred Stock and 4,159,388 shares of Viridian Series A Preferred Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fund II. They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein."}],"balance_after":82349,"derivative":{"underlying":"Common Stock","underlying_shares":82349000},"source":{"system":"sec-edgar","filing":"0000899243-20-029660","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000089924320029660/doc4.xml","form_type":"4"}},{"id":2998159,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":92443,"kind":"person","name":"Fairmount Healthcare Fund GP LLC","position":2,"cik":"0001830383","reported_name":"Fairmount Healthcare Fund GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":47598,"kind":"person","name":"Fairmount Healthcare Fund II GP LLC","position":3,"cik":"0001830382","reported_name":"Fairmount Healthcare Fund II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":4,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":5,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}}],"security":"Series A Non-Voting Convertible Preferred Stock","published_at":"2020-10-29T11:30:05.000Z","date":"2020-10-27","kind":"other","acquired":true,"shares":16505,"ownership":{"direct":false,"nature":"Fairmount Healthcare Fund LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion"},{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 27, 2020, Issuer completed its merger (\"Merger\") with Viridian Therapeutics, Inc. (\"Veridian\"), in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020.  In connection with the Merger, Fairmount Healthcare Fund LP (\"Fund I\") received such shares in exchange for 698,110 shares of Viridian Series Seed Preferred Stock and 804,612 shares of Viridian Series A Preferred Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 27, 2020, Issuer completed its merger (\"Merger\") with Viridian Therapeutics, Inc. (\"Veridian\"), in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020.  In connection with the Merger, Fairmount Healthcare Fund LP (\"Fund I\") received such shares in exchange for 698,110 shares of Viridian Series Seed Preferred Stock and 804,612 shares of Viridian Series A Preferred Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fund I. They disclaim beneficial ownership of securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein."}],"balance_after":16505,"derivative":{"underlying":"Common Stock","underlying_shares":16505000},"source":{"system":"sec-edgar","filing":"0000899243-20-029660","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000089924320029660/doc4.xml","form_type":"4"}},{"id":2998158,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":92443,"kind":"person","name":"Fairmount Healthcare Fund GP LLC","position":2,"cik":"0001830383","reported_name":"Fairmount Healthcare Fund GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":47598,"kind":"person","name":"Fairmount Healthcare Fund II GP LLC","position":3,"cik":"0001830382","reported_name":"Fairmount Healthcare Fund II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":4,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":5,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}}],"security":"Common Stock","published_at":"2020-10-29T11:30:05.000Z","date":"2020-10-27","kind":"other","acquired":true,"shares":438502,"ownership":{"direct":false,"nature":"Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On October 27, 2020, Issuer completed its Merger with Viridian, in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020.  In connection with the Merger, Fairmount Healthcare Fund II LP (\"Fund II\") received such shares in exchange for 3,301,890 shares of Viridian Series Seed Preferred Stock and 4,159,388 shares of Viridian Series A Preferred Stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On October 27, 2020, Issuer completed its Merger with Viridian, in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020.  In connection with the Merger, Fairmount Healthcare Fund II LP (\"Fund II\") received such shares in exchange for 3,301,890 shares of Viridian Series Seed Preferred Stock and 4,159,388 shares of Viridian Series A Preferred Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fund II. They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein."}],"balance_after":438502,"source":{"system":"sec-edgar","filing":"0000899243-20-029660","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000089924320029660/doc4.xml","form_type":"4"}},{"id":2998157,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":92443,"kind":"person","name":"Fairmount Healthcare Fund GP LLC","position":2,"cik":"0001830383","reported_name":"Fairmount Healthcare Fund GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":47598,"kind":"person","name":"Fairmount Healthcare Fund II GP LLC","position":3,"cik":"0001830382","reported_name":"Fairmount Healthcare Fund II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":92444,"kind":"person","name":"Fairmount Healthcare Fund L.P.","position":4,"cik":"0001686157","reported_name":"Fairmount Healthcare Fund L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":5,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks"}}],"security":"Common Stock","published_at":"2020-10-29T11:30:05.000Z","date":"2020-10-27","kind":"other","acquired":true,"shares":87891,"ownership":{"direct":false,"nature":"Fairmount Healthcare Fund LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 27, 2020, Issuer completed its merger (\"Merger\") with Viridian Therapeutics, Inc. (\"Veridian\"), in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020.  In connection with the Merger, Fairmount Healthcare Fund LP (\"Fund I\") received such shares in exchange for 698,110 shares of Viridian Series Seed Preferred Stock and 804,612 shares of Viridian Series A Preferred Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 27, 2020, Issuer completed its merger (\"Merger\") with Viridian Therapeutics, Inc. (\"Veridian\"), in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020.  In connection with the Merger, Fairmount Healthcare Fund LP (\"Fund I\") received such shares in exchange for 698,110 shares of Viridian Series Seed Preferred Stock and 804,612 shares of Viridian Series A Preferred Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fund I. They disclaim beneficial ownership of securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein."}],"balance_after":87891,"source":{"system":"sec-edgar","filing":"0000899243-20-029660","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1686157/000089924320029660/doc4.xml","form_type":"4"}}]}